TPST241018C7500
- 0.10
- 0.000.00%
Tempest Therapeutics Newsroom
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest Therapeutics Analyst Ratings
Buy Rating Affirmed for Tempest Therapeutics Amid Positive Developments and Strategic Roche Collaboration
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
Traders Digest Consumer Inflation Measure as US Equity Futures Drop Pre-Bell
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial With Roche; Shares Jump Pre-Bell
Roche Collaboration for Lead Asset Boosts Tempest
Top Premarket Gainers
Tempest Therapeutics Extends Limited Duration Stockholder Rights Plan; Shares Rise Premarket
Trending Stocks Today | CN Energy Soars 40.7% Pre-Market
Tempest Therapeutics Announces Agreement With Roche for Amezalpat Combo Therapy
Express News | Tempest Therapeutics Inc - Phase 3 Study to Start in Q1 2025
Express News | Tempest Therapeutics Inc - Retains All Rights to Amezalpat
Express News | Tempest Therapeutics Inc - Roche to Supply Atezolizumab, Tempest to Lead Study
Express News | Tempest Announces Agreement With Roche to Support Advancement of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
Express News | Tempest Therapeutics Inc - Rights Plan to Expire After 2025 Annual Meeting Unless Approved